BioNTech maps pivotal oncology milestones for 2026
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
India’s pharmaceutical sector stands at a pivotal inflection point
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Subscribe To Our Newsletter & Stay Updated